Indaptus Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Indaptus Therapeutics, Inc. (INDP) on September 4, 2026, covering events occurring on September 2, 2026. The Company is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
On September 2, 2026, Tim Ruan resigned from the Board of Directors, effective immediately. The Company stated that Mr. Ruan's resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Tim Ruan has resigned from the Board of Directors effective September 2, 2026.
- The resignation was not caused by any disagreement with the Company.
- The report was signed by Junyi Dai, Chief Executive Officer, on September 4, 2026.
- No financial data or operational updates were included in this specific filing.